155 related articles for article (PubMed ID: 31484540)
1. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.
Liu Y; Bian T; Zhang Y; Zheng Y; Zhang J; Zhou X; Xie J
Diagn Pathol; 2019 Sep; 14(1):100. PubMed ID: 31484540
[TBL] [Abstract][Full Text] [Related]
2. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
4. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
5. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.
Vazquez I; Papaleo N; Lop J; Puiggros A; Sanchez-Gonzalez B; Diez-Feijoo R; Gimeno E; Andrade-Campos M; Salar A; Espinet B; Salido M; Tapia G; Carreras J; Ferrer A; Arenillas L; Calvo X; Colomo L
Virchows Arch; 2021 Dec; 479(6):1073-1078. PubMed ID: 33811533
[TBL] [Abstract][Full Text] [Related]
6. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
Rymkiewicz G; Grygalewicz B; Chechlinska M; Blachnio K; Bystydzienski Z; Romejko-Jarosinska J; Woroniecka R; Zajdel M; Domanska-Czyz K; Martin-Garcia D; Nadeu F; Swoboda P; Rygier J; Pienkowska-Grela B; Siwicki JK; Prochorec-Sobieszek M; Salaverria I; Siebert R; Walewski J
Mod Pathol; 2018 May; 31(5):732-743. PubMed ID: 29327714
[TBL] [Abstract][Full Text] [Related]
8. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons.
Hutchison RE; Finch C; Kepner J; Fuller C; Bowman P; Link M; Schwenn M; Laver J; Desai S; Barrett D; Murphy SB
Ann Oncol; 2000; 11 Suppl 1():35-8. PubMed ID: 10707776
[TBL] [Abstract][Full Text] [Related]
9. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation.
Rodig SJ; Vergilio JA; Shahsafaei A; Dorfman DM
Am J Surg Pathol; 2008 Jan; 32(1):113-22. PubMed ID: 18162778
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.
Chapman-Fredricks J; Younes SF; Fan YS; Sandoval-Sus JD; Natkunam Y; Lossos IS
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):200-4. PubMed ID: 22914613
[TBL] [Abstract][Full Text] [Related]
12. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
13. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
Grygalewicz B; Woroniecka R; Rymkiewicz G; Rygier J; Borkowska K; Kotyl A; Blachnio K; Bystydzienski Z; Nowakowska B; Pienkowska-Grela B
Am J Clin Pathol; 2017 Dec; 149(1):17-28. PubMed ID: 29272887
[TBL] [Abstract][Full Text] [Related]
14. [Expression and significance of HGAL and LMO2 in follicular lymphoma].
Zhang F; Luo D; Luo X; Chen Y; Xu J; Chen J; Zhuang H; Liu Y
Zhonghua Bing Li Xue Za Zhi; 2016 Feb; 45(2):83-5. PubMed ID: 26879427
[TBL] [Abstract][Full Text] [Related]
15. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ
Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438
[TBL] [Abstract][Full Text] [Related]
16. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
17. LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.
Patel JL; Pournazari P; Haggstrom SJ; Kosari F; Shabani-Rad MT; Natkunam Y; Mansoor A
Histopathology; 2014 Jan; 64(2):226-33. PubMed ID: 24330148
[TBL] [Abstract][Full Text] [Related]
18. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
Haralambieva E; Boerma EJ; van Imhoff GW; Rosati S; Schuuring E; Müller-Hermelink HK; Kluin PM; Ott G
Am J Surg Pathol; 2005 Aug; 29(8):1086-94. PubMed ID: 16006805
[TBL] [Abstract][Full Text] [Related]
19. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
20. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
